SEC Company Response from ANAVEX LIFE SCIENCES CORP. (AVXL) (CIK 0001314052) (AVXL) — Feb 15, 2008
ANAVEX LIFE SCIENCES CORP. (AVXL) (CIK 0001314052)
Date: Feb. 15, 2008 · CIK: 0001314052 · Accession: 0001085037-08-000216
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 000-51652
Referenced dates: February 11, 2008
Letter
RE:
February 15, 2008
United States Securities and Exchange Commission
Division of Corporate finance
100F Street, NE
Washington, DC 20549-6010
Attn: Sasha Parikh
Anavex Life Sciences Corp.
Form 10-KSB for the year ended September 30, 2007
File No. 000-51652
Further to your letter dated February 11, 2008 I wish to advise that the Report from the Independent Registered Public Accounting Firm – Amisano Hanson that was delivered to Anavex Life Sciences Corp was a signed report however in the process of preparing the file for EDGAR a formatting error was made and was not identified prior to filing.
I have retained the originally singed report for our records.
We confirm that future reports will include the typed signature of our independent accountants.
Additionally we acknowledge the following:
•
the company is responsible for the adequacy and accuracy of the disclosure in the filing;
•
staff comments or changes to disclosure in response to staff comments do not foreclose the Commission from taking any action with respect to the filing; and
•
the company may not assert staff comments as a defence in any proceeding initiated by the Commission or any person under the federal securities laws of the United States.
Sincerely,
/s/ Harvey Lalach
Show Raw Text
CORRESP
1
filename1.htm
February 15, 2008
United States Securities and Exchange Commission
Division of Corporate finance
100F Street, NE
Washington, DC 20549-6010
Attn: Sasha Parikh
RE:
Anavex Life Sciences Corp.
Form 10-KSB for the year ended September 30, 2007
File No. 000-51652
Further to your letter dated February 11, 2008 I wish to advise that the Report from the Independent Registered Public Accounting Firm – Amisano Hanson that was delivered to Anavex Life Sciences Corp was a signed report however in the process of preparing the file for EDGAR a formatting error was made and was not identified prior to filing.
I have retained the originally singed report for our records.
We confirm that future reports will include the typed signature of our independent accountants.
Additionally we acknowledge the following:
•
the company is responsible for the adequacy and accuracy of the disclosure in the filing;
•
staff comments or changes to disclosure in response to staff comments do not foreclose the Commission from taking any action with respect to the filing; and
•
the company may not assert staff comments as a defence in any proceeding initiated by the Commission or any person under the federal securities laws of the United States.
Sincerely,
/s/ Harvey Lalach
Harvey Lalach, President
Anavex Life Sciences Corp.
14 rue Kleberg, Geneve, Switzerland CH-1201 Ph: 250-864-2740 Fax: 250-764-9701